Group 1 - The company Kewah Bio expects a net loss attributable to shareholders of 580 million to 740 million yuan for 2025, with basic earnings per share loss estimated at 1.1276 to 1.4387 yuan [1] - In the same period last year, the company reported a net loss of approximately 641 million yuan, with a basic earnings per share loss of 1.2687 yuan [1] - The primary reason for the performance change is significant adverse impact from asset impairment provisions, which the company plans to assess and test comprehensively based on industry trends and actual operating conditions [1] Group 2 - The IVD industry is facing intensified competition due to policy changes and market pressures, leading to a decline in both revenue scale and product gross margins year-on-year [1] - Factors such as medical procurement policies, DRG payment reform, mutual recognition of test results, adjustments in testing service fees, and unbundling of testing packages are reshaping the competitive landscape of the industry [1] - The demand for certain routine testing projects is contracting, coupled with downward pressure on product prices, which directly affects the company's profitability [1]

Core Viewpoint - The company, Kehua Bio, forecasts a significant net loss for the year 2025, estimating a loss of between 5.80 billion to 7.40 billion yuan for net profit attributable to shareholders, and a loss of 5.90 billion to 7.50 billion yuan for net profit after deducting non-recurring gains and losses. This reflects the challenges faced in the IVD industry due to intensified competition and adverse policy impacts [1]. Summary by Relevant Sections Financial Performance - The company anticipates a net loss of 5.80 billion to 7.40 billion yuan for 2025, with a net loss of 5.90 billion to 7.50 billion yuan after excluding non-recurring items [1]. Factors Affecting Performance - Major factors impacting performance include: 1. Asset impairment provisions significantly affecting profits, as the company conducts comprehensive assessments and plans to recognize impairment losses based on industry trends and operational realities [1]. 2. Increased market competition and adverse industry policies leading to a decline in both volume and price, resulting in reduced revenue and gross margin [1]. 3. The company is committed to its strategic positioning of "comprehensive yet precise" and "integrated innovation," focusing on national health needs while implementing various measures for stable development [1]. Strategic Initiatives - The company plans to: 1. Strengthen research and sales collaboration to uncover new growth drivers, maintaining R&D investment and enhancing its sales and service network domestically and internationally [1]. 2. Deepen lean management and promote digital transformation to optimize resource allocation and improve operational efficiency, thereby laying a solid foundation for high-quality development [1].

Group 1: Company Performance Overview - In the first half of 2025, the company achieved a total outpatient and emergency service volume of 1.3191 million visits, a year-on-year increase of 5.42% [2] - The inpatient service volume reached 96,300 visits, a year-on-year decrease of 4.01% [2] - The company reported operating revenue of 2,034.31 million yuan, a year-on-year decrease of 15.95% [2] - The net profit attributable to shareholders was -164.96 million yuan, a year-on-year improvement of 4.98% [2] - The net operating cash flow was 592.54 million yuan, an increase of 12.75% compared to the same period last year [2] Group 2: Hospital-Specific Performance - Xi'an Gaoxin Hospital had an outpatient and emergency service volume of 578,700 visits, a year-on-year increase of 3.04% [3] - Inpatient service volume at Xi'an Gaoxin Hospital was 30,300 visits, a year-on-year decrease of 6.48% [3] - The hospital's operating revenue was 638.74 million yuan, a year-on-year decrease of 17.30% [3] - The net profit for Xi'an Gaoxin Hospital was 30.98 million yuan, a year-on-year decrease of 37.48% [3] - Xi'an International Medical Center Hospital had an outpatient and emergency service volume of 740,500 visits, a year-on-year increase of 7.37% [3] - Inpatient service volume at the center was 66,000 visits, a year-on-year decrease of 2.80% [3] - The center's operating revenue was 1,383.27 million yuan, a year-on-year decrease of 15.37% [3] - The net profit for the center was -113.21 million yuan, a year-on-year decrease of 44.63% [3] Group 3: Strategic Initiatives and Future Outlook - The company is focusing on cost control and efficiency improvement through bed integration and department optimization [4] - It aims to enhance service quality and patient experience while implementing a differentiated business strategy [4] - The company is actively adapting to industry changes to achieve orderly expansion of service scale and continuous optimization of operational efficiency [6] - Research in stem cell therapy is ongoing, with over 500 testing projects related to hematological diseases, tumor diagnosis, and preventive medicine [4]

Group 1: Company Performance Overview - In the first half of 2025, the company achieved a total outpatient and emergency service volume of 1.3191 million, a year-on-year increase of 5.42% [4] - The company reported operating revenue of CNY 2,034.31 million, a decrease of 15.95% year-on-year, and a net profit attributable to shareholders of CNY -164.96 million, a year-on-year decrease in loss of 4.98% [4] - The operating cash flow net amount was CNY 592.54 million, an increase of 12.75% compared to the same period last year [4] Group 2: Service and Operational Improvements - The company established a senior care center with 100 beds to cater to the needs of elderly patients, including those with Alzheimer's and other disabilities [2] - The company’s hospitals completed 636 clinical application filings for restricted technologies and published 39 SCI papers, enhancing their academic influence [2] - The company improved patient service experience by optimizing the hospitalization settlement and medical insurance reimbursement processes [3] Group 3: Financial Metrics and Cost Management - In Q2 2025, the company achieved operating revenue of CNY 1.037 billion, a quarter-on-quarter increase of 4.02% [4] - The management expense ratio in Q2 was 13.12%, a decrease of 0.95 percentage points from the previous quarter [4] - The company implemented cost control measures, including optimizing personnel costs and enhancing procurement efficiency [6] Group 4: Patient Demographics and Market Reach - The proportion of out-of-town patients at Xi'an Gaoxin Hospital increased to 35%, while at Xi'an International Medical Center Hospital, it rose to 42% from less than 10% [7] - The company is adapting to DRG payment reform, stabilizing inpatient service volume while expanding outpatient services [6] Group 5: Future Outlook and Strategic Initiatives - The company plans to enhance medical quality and service experience while implementing differentiated strategies to build competitive advantages [9] - The proton therapy center, set to open in 2025, will be the first of its kind in Northwest China, significantly improving cancer treatment capabilities in the region [9]